Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

INTRODUCTION: The development of immune-related adverse events (irAEs) has been associated with improved efficacy of immune checkpoint inhibitors in patients with urothelial cancer, melanoma, and NSCLC. Whether this association exists in patients with SCLC is currently unknown. METHODS: We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Naqash, Abdul Rafeh, Naidoo, Jarushka, Sehgal, Kartik, Miller, Adam, Kehl, Kenneth, Venkatraman, Deepti, Sands, Jacob, Lamberti, Giuseppe, Recondo, Gonzalo, Zhang, Jiajia, Macherla, Shravanti, Baig, Sameer, Walker, Paul, Rangachari, Deepa, Gainor, Justin F., Costa, Daniel B., Rizvi, Naiyer, Sholl, Lynette M., Nishino, Mizuki, Henick, Brian, Farago, Anna F., Awad, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474257/
https://www.ncbi.nlm.nih.gov/pubmed/34589955
http://dx.doi.org/10.1016/j.jtocrr.2020.100074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474257/
https://www.ncbi.nlm.nih.gov/pubmed/34589955
http://dx.doi.org/10.1016/j.jtocrr.2020.100074

Ejemplares similares